Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IRADIMED CORP Director's Dealing 2025

Dec 12, 2025

32324_dirs_2025-12-12_adc39d3b-674d-41ff-bf13-33b422a2718f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2025-12-11

Reporting Person: GLENN JOHN (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-11 Common Stock S 14468 $97.26 Disposed 7894 Direct
2025-12-11 Common Stock S 532 $98.09 Disposed 7362 Direct
2025-12-11 Common Stock M 1812 Acquired 9174 Direct
2025-12-11 Common Stock F 714 $97.38 Disposed 8460 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-12-11 Restricted Stock Units $ M 1812 Disposed Common Stock (1812) Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $97.00 to $97.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.